Two doses of Pfizer's covid vaccine were 82.7% effective at preventing hospitalizations among 5- to 11-year olds. Separately, an experimental oral covid vaccine is reportedly showing promise, and a Gates Foundation study found existing boosters were surprisingly good against BA.5.
CIDRAP: Pfizer Vaccine 83% Effective Against Hospital Omicron Illness In Kids 5 To 11 In 5- to 11-year-old children, two doses of the Pfizer/BioNTech COVID-19 vaccine were 36.8% effective in preventing all SARS-CoV-2 infections, 63.5% against test-confirmed cases, and 82.7% against hospitalization amid the Omicron variant surge in Singapore, finds a real-world study published yesterday in the New England Journal of Medicine (NEJM). (7/21)
Reuters: Oral Vaccine Shows Promise An experimental COVID-19 vaccine in the form of an oral tablet has shown promising immune responses in a small preliminary trial designed mainly to evaluate its safety, according to drug manufacturer Vaxart Inc (VXRT.O). The South San Francisco, California-based company had earlier said the tablet was well tolerated, with no one dropping out of the study because of adverse effects. On Tuesday, they reported on immune responses in the 35 healthy volunteers who received the tablet. (Lapid, 7/21)
Fortune: Bill & Melinda Gates Foundation Partly Funded A Study About COVID-19 Booster Shots For The BA.5 Omicron Subvariant. Surprise: Boosters Still Work Getting a booster can generate enough of an antibody response and protection from severe disease outcomes to hold up against any of the new Omicron subvariants, according to an early release paper published this week in Science. That extends to BA.5, now the most prevalent COVID strain in the U.S. and a driver of COVID-19 reinfections across the country. (Mui, 7/21)
CIDRAP: In COVID-19 Omicron Patients, High Blood Pressure Doubles Risk Of Hospitalization People who have high blood pressure and Omicron-variant COVID-19 are at more than double the risk for hospitalization—even if they received three mRNA vaccine doses, according to a single-center study published yesterday in Hypertension. (Van Beusekom, 7/21)
CIDRAP: COVID-19 In Third Trimester—But Not Earlier—Linked To Preterm Birth A new study of more than 5,000 women shows that contracting COVID-19 during the third trimester of pregnancy is linked to a more than double increased risk of preterm birth. The study was published yesterday in PLOS One. (7/21)
Stat: AI Shows Potential To Reduce Sepsis Deaths In Real-World Studies Three studies published Thursday found that an AI platform developed by Bayesian Health and Johns Hopkins University reduced deaths from sepsis by 18.2% in real-world use when physicians responded promptly to its alerts, a finding that suggests AI has potential to become an important tool in battling a leading cause of deaths in hospitals. (Muthukumar, 7/21)
We want to hear from you: Contact Us
Three Things About the Abortion Debate That Many People Get Wrong
A Nearly Century-Old Maternity Home for Teens in the South Makes Plans for Expansion
‘So Rudderless’: A Couple’s Quest for Autism Treatment for Their Son Hits Repeated Obstacles
KHN’s ‘What the Health?’: Drug Price Bill Is a Go in the Senate
© 2022 Kaiser Family Foundation. All rights reserved.
Thank you for your interest in supporting Kaiser Health News (KHN), the nation’s leading nonprofit newsroom focused on health and health policy. We distribute our journalism for free and without advertising through media partners of all sizes and in communities large and small. We appreciate all forms of engagement from our readers and listeners, and welcome your support.
KHN is an editorially independent program of KFF (Kaiser Family Foundation). You can support KHN by making a contribution to KFF, a non-profit charitable organization that is not associated with Kaiser Permanente.
Click the button below to go to KFF’s donation page which will provide more information and FAQs. Thank you!